Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
Explore this paper's citation graph
Summary
Doripenem appears to be a promising, potent carbapenem for parenteral use against contemporary Gram-negative bacilli producing various beta-lactamases.
- Type
- article
- Published
- 2005-05-01
- Cited by
- 125
- References
- 19
- OpenAlex
- https://openalex.org/W1970948691
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:25652705
Keywords
Ertapenem, Doripenem, Meropenem, Imipenem, Microbiology
References
- A comparison of the antimicrobial activity of meropenem and selected broad-spectrum antimicrobials tested against multi-drug resistant Gram-negative bacilli including bacteraemic Salmonella spp.: initial studies for the MYSTIC programme in India.
- Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard
- Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : Approved standard
- Emerging carbapenemases in Gram-negative aerobes.
- A novel 1 beta-methylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1 beta-methylcarbapenems.
- Plasmid-mediated dissemination of the metallo-beta-lactamase gene blaIMP among clinically isolated strains of Serratia marcescens
- Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I.
- In Vitro Antibacterial Activity of S-4661, a New Parenteral Carbapenem, against Urological Pathogens Isolated from Patients with Complicated Urinary Tract Infections
- Comparative in vitro Activity of S-4661, a New Parenteral Carbapenem, and Other Antimicrobial Agents against Respiratory Pathogens
- Recent developments in carbapenems
- Activities of Doripenem (S-4661) against Drug-Resistant Clinical Pathogens
- Emergence in Klebsiella pneumoniae and Enterobacter cloacae Clinical Isolates of the VIM-4 Metallo-β-Lactamase Encoded by a Conjugative Plasmid
- Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase.
- Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential
- Comparative Activities of Doripenem versus Isolates, Mutants, and Transconjugants of Enterobacteriaceae and Acinetobacter spp. with Characterized β-Lactamases
- Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
- Properties and potential of ertapenem.
- In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens.
- Metallo-beta-lactamase-producing gram-negative bacilli: laboratory-based surveillance in cooperation with 13 clinical laboratories in the Kinki region of Japan.
- In Vitro Antimicrobial Activity of Doripenem, a New Carbapenem
Cited by
- Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside.
- In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens.
- β-Lactamase-producing bacteriaHow can I resist you?
- Doripenem (Doribax): The Newest Addition to the Carbapenems
- DETECTION AND ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF ESBL PRODUCING GRAM NEGATIVE BACTERIA
- Electroanalytical Determination of Doripenem using a Screen-Printed Electrode
- Removal of Doripenem During Hemodialysis and the Optimum Dosing Regimen for Patients Undergoing Hemodialysis
- New developments in carbapenems.
- Open-Label Study To Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants Less than 12 Weeks in Chronological Age
- What's new and not so new on the antimicrobial horizon?
- Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens
- In Vitro Activity of Doripenem, a Carbapenem for the Treatment of Challenging Infections Caused by Gram-Negative Bacteria, against Recent Clinical Isolates from the United States
- A Review of Doripenem for the Treatment of Serious Bacterial Infections
- Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem.
- Comparative Review of the Carbapenems
- Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients.
- Investigational treatments for postoperative surgical site infections
- In Vitro Activity Studies of Doripenem and Two Other Carbapenems Tested Against Pseudomonas aeruginosa and Other Non-Fermentative Bacilli
- Doripenem
- Treatment of bacterial urinary tract infections: presence and future.
Related papers
- Doripenem Versus Bacteria: An Emerging Battleground
- In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae.
- Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii
- Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities
- Discordance of meropenem versus imipenem activity against Acinetobacter baumannii.
- Recent updates of carbapenem antibiotics.
- Conformational flexibility in carbapenem hydrolysis drives substrate specificity of the class D carbapenemase OXA-24/40
- Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem.
- Carbapenems: A Short Review about their Current Status